Kazia Therapeutics LTD Schedule 13G passive stakes

Ikarian Capital, LLC and Neil Shahrestani have jointly reported a beneficial ownership of 4.9% in Kazia Therapeutics Limited's American Depositary Shares.

Jorey Chernett has filed a Schedule 13G, reporting beneficial ownership of 2,114,649 American Depositary Shares in Kazia Therapeutics Ltd, representing 18.5% of the class.

Jorey Chernett has reported an increased beneficial ownership of 13.90% in Kazia Therapeutics Ltd, holding 1,588,129 American Depositary Shares.

Alumni Capital LP and its affiliates have filed an exit statement, reporting zero beneficial ownership in Kazia Therapeutics Ltd. American Depository Shares.

Dauntless Investment Group, LLC filed an amended Schedule 13G, reporting a 0.0% passive ownership stake in Kazia Therapeutics LTD.

Lynwood Capital Management Inc., Ben Shapiro, and Lynwood Opportunities Master Fund have jointly reported a 5.4% beneficial ownership stake in Kazia Therapeutics Limited.

Dauntless Investment Group, LLC reported a 9.99% beneficial ownership stake in Kazia Therapeutics Ltd, comprising American Depository Shares and Pre-funded Warrants.

Alumni Capital LP and its affiliates have disclosed a 9.99% beneficial ownership stake in Kazia Therapeutics Limited through various purchase agreements and warrants.

Dauntless Investment Group, LLC has disclosed a passive 8.4% ownership stake in Kazia Therapeutics Ltd, holding 115,769 American Depository Shares.

Dauntless Investment Group, LLC has disclosed a passive ownership stake of 5.87% in Kazia Therapeutics Ltd, holding 80,617 American Depository Shares.

Jorey Chernett has reported a beneficial ownership of 9.99% of Kazia Therapeutics Ltd.'s American Depositary Shares, as detailed in a recent Schedule 13G filing with the SEC.

Alumni Capital LP, along with its general partner Alumni Capital GP LLC and manager Ashkan Mapar, has filed an amended Schedule 13G, confirming a passive beneficial ownership of 9.99% in Kazia Therapeutics Limited through warrants.

Alumni Capital LP, along with its general partner and manager, has disclosed a 9.99% beneficial ownership stake in Kazia Therapeutics Limited, while also holding warrants that could significantly increase their ownership if certain exercise limitations were removed.